Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.43 |
| ▸ | MMP2 | P08253 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ANPEP | P15144 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2298094 | 1.00 | KCNN4 (0.43) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL992574 | 1.00 | KCNN4 (0.43) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL6036541 | 0.89 | KIF11 (0.39) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL29276034 | 0.87 | MMP2 (0.41) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL26062663 | 0.87 | MMP2 (0.41) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL31696759 | 0.87 | MMP2 (0.41) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL5200976 | 0.87 | MMP2 (0.41) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL3548775 | 0.87 | MMP2 (0.41) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL3548773 | 0.87 | MMP2 (0.41) | KCNN4MMP2KMT2AANPEPCYP1A2 | |
| SCHEMBL6399801 | 0.86 | NR1H2 (0.46) | MMP2ANPEPCYP1A2CYP2C19POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4288426-B1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250320234-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | PRETZEL THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | US | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| EP-4603105-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-20 | — | — | EP | disclosed |
| EP-4592308-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-30 | — | — | EP | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| EP-4559902-A2 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | Imago Biosciences Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4512818-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-02-26 | — | — | EP | disclosed |
| US-4698231-A | Sweetening with L-aminodicarboxylic acid amides | GENERAL FOOD CORPORATION (US) | 1987-10-06 | — | — | US | disclosed |
| US-4676989-A | Sweetening with cycloalkyl ethers and thioethers of dipeptides | GENERAL FOODS CORPORATION (US) | 1987-06-30 | — | — | US | disclosed |
| US-4654219-A | ARTIFICIAL SWEETENERS | GENERAL FOODS CORPORATION (US) | 1987-03-31 | — | — | US | disclosed |
| US-4654439-A | FOOD SWEETENERS | GENERAL FOODS CORPORATION (US) | 1987-03-31 | — | — | US | disclosed |
| US-4650688-A | DIPEPTIDES | GENERAL FOODS CORPORATION (US) | 1987-03-17 | — | — | US | disclosed |
| US-4638071-A | ARTIFICIAL SWEETENERS | GENERAL FOODS CORPORATION (US) | 1987-01-20 | — | — | US | disclosed |
| US-4622417-A | DIETETICS | GENERAL FOODS CORPORATION (US) | 1986-11-11 | — | — | US | disclosed |
| US-4622418-A | LOW CALORIE SWEETENERS | GENERAL FOODS CORPORATION (US) | 1986-11-11 | — | — | US | disclosed |
| US-4603011-A | ARTIFICIAL SWEETRENERS | GENERAL FOODS CORPORATION (US) | 1986-07-29 | — | — | US | disclosed |
| EP-0186173-A2 | L-Aminodicarboxylic-(0-cycloalkyl)-L-aminocarboxylate alkyl esters, an edible composition containing same as sweeteners and a method for sweetening an edible composition | GENERAL FOODS CORPORATION (US) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320234-A1 | LONP1 INHIBITOR COMPOUNDS, USES AND METHODS | LONP1, NLN, ACAT1 | KCNN4 4709/4885MMP2 2061/4885KMT2A 3897/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | KCNN4 3688/4885MMP2 4305/4885KMT2A 1250/4885 |
| US-12473331-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | KCNN4 4639/4885MMP2 2512/4885KMT2A 1548/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | KCNN4 3688/4885MMP2 4305/4885KMT2A 1250/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | KCNN4 3236/4885MMP2 3681/4885KMT2A 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.